Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT05148871
PHASE2/PHASE3
Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine
Sponsor: Vaxine Pty Ltd
View on ClinicalTrials.gov
Summary
A study to assess the effect of varying the time interval between doses on the immunogenicity of an adjuvanted recombinant spike protein Covid-19 vaccine (Spikogen/Covax-19)
Official title: A Phase 2b Study to Assess the Effect of Dose Interval on the Effectiveness of a Protein-based Covid-19 Vaccine (Spikogen® Vaccine)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2022-03-01
Completion Date
2024-10-06
Last Updated
2024-08-07
Healthy Volunteers
Yes
Conditions
Interventions
BIOLOGICAL
Spikogen/Covax-19
Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant
Locations (1)
ARASMI
Adelaide, South Australia, Australia